Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Authors	Gerald Chi, Megan K Yee, Alpesh N Amin, Samuel Z Goldhaber, Adrian F Hernandez, Russell D Hull, Alexander T Cohen, Robert A Harrington, C Michael Gibson
Journal	Circulation (Circulation) Vol. 137 Issue 1 Pg. 91-94 (01 02 2018) ISSN: 1524-4539 [Electronic] United States
PMID	29279341 (Publication Type: Comparative Study, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Anticoagulants Benzamides Enoxaparin Factor Xa Inhibitors Fibrinolytic Agents Pyridines betrixaban
Topics	Anticoagulants (administration & dosage, adverse effects) Benzamides (administration & dosage, adverse effects) Double-Blind Method Drug Administration Schedule Enoxaparin (administration & dosage, adverse effects) Factor Xa Inhibitors (administration & dosage, adverse effects) Fibrinolytic Agents (administration & dosage, adverse effects) Humans Inpatients Patient Readmission Pyridines (administration & dosage, adverse effects) Risk Factors Time Factors Treatment Outcome Venous Thromboembolism (diagnosis, etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!